Delving into the Latest Updates on MSD LLC (Texas) with Synapse

概览

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

ER x PR	1

关联

1

项与 MSD LLC (Texas) 相关的药物

Ethinyl Estradiol/Etonogestrel

依托孕烯炔雌醇环

靶点

ER x PR

作用机制

ERs激动剂 [+1]

在研机构

MSD LLC (Texas) [+1]

原研机构

Merck Sharp & Dohme Corp.

在研适应症

避孕

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2001-10-03

100 项与 MSD LLC (Texas) 相关的临床结果

登录后查看更多信息

0 项与 MSD LLC (Texas) 相关的专利（医药）

登录后查看更多信息

21

项与 MSD LLC (Texas) 相关的文献（医药）

2018-01-01·[Nihon koshu eisei zasshi] Japanese journal of public health

[A nationwide survey of PPSV23 vaccine coverage rates and their related factors among the elderly in Japan, 2016].

Article

作者: Akira Watanabe ; Mari Oba ; Shin-Ichi Kanazu ; Yoshitaka Murakami ; Yuuji Nishiwaki

2017-01-01·Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes

Review

作者: Yuka Ito ; Masahiko Mori ; Taro Okamoto ; Yuki Matsumoto

2017-01-01·Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C

Article

作者: Keisuke Nakamura ; Ernest Asante-Appiah ; Takashi Iwasa ; Kiyoshi Kinoshita

This paper presents the preclin. and clin. properties of elbasvir and grazoprevir in novel therapeutic agents for hepatitis-C.The paper describes the combination therapy that is effective in a wide range of hepatitis C chronically infected patients with a history of treatment.The therapy has a high antiviral effect even in resistant mutation cases.

100 项与 MSD LLC (Texas) 相关的药物交易

登录后查看更多信息

100 项与 MSD LLC (Texas) 相关的转化医学

登录后查看更多信息